Daily Stock Analysis, EBIO, Eleven Biotherapeutics Inc, priceseries

Eleven Biotherapeutics Inc. Daily Stock Analysis
Stock Information
Open
2.74
Close
3.29
High
3.44
Low
2.73
Previous Close
2.65
Daily Price Gain
0.64
YTD High
3.50
YTD High Date
May 2, 2018
YTD Low
0.75
YTD Low Date
Jan 2, 2018
YTD Price Change
2.46
YTD Gain
296.39%
52 Week High
3.50
52 Week High Date
May 2, 2018
52 Week Low
0.62
52 Week Low Date
Nov 10, 2017
52 Week Price Change
1.83
52 Week Gain
125.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 2. 2018
0.95
Mar 13. 2018
1.04
7 Trading Days
9.56%
Link
LONG
Apr 3. 2018
1.25
Apr 13. 2018
1.39
8 Trading Days
11.56%
Link
LONG
Apr 19. 2018
1.62
May 8. 2018
2.68
13 Trading Days
65.32%
Link
Company Information
Stock Symbol
EBIO
Exchange
NasdaqGM
Company URL
http://www.elevenbio.com
Company Phone
617-444-8550
CEO
Stephen Allen Hurly
Headquarters
Massachusetts
Business Address
245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001485003
About

Eleven Biotherapeutics, Inc. is a preclinical stage biopharmaceutical company engages in medical development. It involves in the management of proprietary protein engineering platform called AMP-Rx for the development and discovery of protein therapeutics to treat diseases of the eye. Through therapeutic approach, it focuses on structural biology of cytokines to design and generate product candidate called EBI-031, that targets Diabetic Macular Edema diseases. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Description

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. The company was founded in 2008 and is based in Cambridge, Massachusetts.